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Aim: The research was aimed to analyze a level of triglycerides in blood serum as a possible new marker of toxicity, particularly 
in patients with excess body weight, receiving cisplatin. Materials and Methods: Study involved 20 oncological patients with stage 
III lung cancer, who received palliative treatment with cisplatin. High-performance liquid chromatography was used for quantitative 
determination of pure cisplatin in urine and blood samples. Cisplatin concentration of the test samples was determined based on the 
data obtained from the calibration graph. Results: Quantitative determination of pure cisplatin is quite complicated. The elimination 
half-time for one of the groups was observed higher almost by half than for other patients. Higher dose of cisplatin showed a significant 
association with increase in triglyceride levels. We found a close correlation between body mass index and triglyceride changes during 
chemotherapy (p = 0.001; r = 0.67). The results indicate that a higher body mass index gives higher fluctuations of triglyceride levels 
in blood serum. Analyses of correlation between level of triglycerides and elimination half-time show that by an increase in the level 
of triglycerides in the blood serum cisplatin elimination half-time is prolonged (R2 Linear = 0.596). Cisplatin concentration in urine 
is higher and elimination takes longer time at elevated levels of triglycerides, where close correlation between fraction of excreted sub-
stance in urine and concentration parameters was seen (p < 0.01). Also good correlation for body mass index with fraction of excreted 
substance in urine and concentration parameters was observed (p < 0.05). Conclusion: Clearance of cisplatin, which was determined 
by the chromatographic method, is reduced in individuals with increased adipose tissue mass. Research data suggest that overweight 
affects cisplatin elimination from the body. The greater body fat mass can contribute to a greater rise of triglyceride level in blood serum. 
Triglycerides in blood plasma may serve as an additional indicator of higher cisplatin toxicity as a cardiotoxicity marker.
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Cancer is a major burden of disease worldwide. Each 
year, tens of millions of people are diagnosed with can-
cer around the world, and more than half of the patients 
eventually die from it. In many countries, cancer ranks 
the second most common cause of death following 
cardiovascular diseases [1].
Increase in cancer incidence is due to the aging 
of the population (in most cases, the tumors are diag-
nosed in older people), as well as the high prevalence 
of risk factors. The risk factors that have a significant 
impact on mortality from malignant tumors are: an in-
creased body mass index (BMI), inadequate fruit and 
vegetable consumption, low physical activity, tobacco 
and alcohol consumption, air pollution, unsafe sex, 
various manipulations made in inappropriate environ-
ment and circumstances (preventive and therapeutic 
injections, tattooing, etc.). World Health Organiza-
tion (WHO) data show that 35% of cancer deaths are 
caused by these risk factors [2].
Survival rates of cancer patients are affected 
by various factors, such as tumor localization, clini-
cally morphological risk factors (patient age, tumor 
morphological variant, tumor differentiation grade, 
stage of disease, reproductive factors, etc.), the pa-
tient’s general health, co-existing conditions, specific 
anti-cancer treatment options.
Chemotherapy is one of cancer treatment op-
tions. In chemotherapy, anticancer agents that kill 
the cancer cells in the body are used. Even if the 
cancer is removed with a surgery, cancer cells may 
be located in nearby tissue or elsewhere in the body. 
The aim of chemotherapy is to treat cancer in several 
ways: either to reduce tumor volume before surgery 
or irradiation, or eradicate cancer cells that may 
be dispersed in the surrounding tissues or organs 
after tumor surgery (i.e. preventive chemotherapy), 
or relieve cancer symptoms (such as pain), or to con-
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trol the tumor growth if the tumor has already spread 
(palliative therapy).
Each chemotherapy drug has its own internation-
ally defined dose of administration, which is calculated 
by taking into account body square meters. Dose 
of drug is calculated individually for each patient 
depending on body weight and height. The pa-
tient’s gene ral condition and co-morbidity is also 
taken into account. Individuals respond differently 
to received chemotherapy and this response may have 
significant clinical importance. Calculation of a definite 
dose of chemotherapy reduces the possible toxic re-
actions of drugs [3]. There are 5 basic conditions that 
determine treatment tactics, i.e., the right medication, 
right patient, right dosage, right administration route 
and right timing [4]. This helps a physician to make 
therapy more rational and avoid therapeutic errors, 
as too small doses of medication have no therapeutic 
effect and that affects overall survival and disease-free 
period, while too high dose increases the toxic effects 
in the body for up to a possible death.
High-performance liquid chromatography (HPLC) 
is irreplaceable modern analytical method for the 
separation and identification of different chemical 
compounds in both simple and in highly complex test 
samples. Its main advantage is speed and accuracy. 
HPLC is currently the most popular method in bio-
chemistry, in particular for pharmacokinetic and phar-
macodynamic studies. When the smaller particle size 
of separation column is used (ultra high-performance 
liquid chromatography — UHPLC), separation method 
goes more effective and more sensitive. UHPLC, with 
its shorter analysis time and quicker column equilibra-
tion, is ideally suited to rapid method development.
MATERIAls AND METHODs
Patients. Patient group with 20 cancer patients 
was established for determination of cisplatin in bio-
logical liquids — blood and urine. The stage III lung 
cancer patients who received palliative treatment with 
cisplatin were selected for this study. Based on BMI 
patients were divided into two groups. One group were 
patients where the BMI < 29.0 kg/m2, another of BMI 
> 29.0 kg/m2. Patients received a dose of cisplatin 
calculated at 75 mg/m2. The patient blood serum tri-
glyceride levels additional was to evaluated the pharma-
cokinetics of cisplatin relationship with body fat mass.
The serum material for determination of cisplatin 
was collected as follows — blood plasma (2 ml, purple 
tube), 0 (prior to treatment), 20, 40, 60, 120 and 
180 min, 24, 48 and 72 h after the end of the infu-
sion (duration of cisplatin infusion 1.00 h). A sample 
of blood allowed clotting for 30 min at the room tem-
perature, then centrifuged for 10 min × 2500 rpm, then 
frozen at –20 °C till further analyses.
Cisplatin analysis by high-performance liquid 
chromatography-mass spectrometry (HPLC-MS). 
HPLC combined with mass spectrometry (MS) was 
used to determine the presence of cisplatin in blood 
and urine samples. All solvents used were of analytical 
grade. Acetonitrile and formic acid were purchased 
from Sigma-Aldrich (St. Louis, USA). The used deio-
nized water (18.2 MΩ) was prepared by a Milli-Q water 
purification system from Millipore (Billerica, Massa-
chusetts, USA). Chromatographic analyses performed 
on a modular UHPLC system, Agilent 1290 Infinity 
series (Agilent Technologies). Liquid chromatogra-
phy (LC) separations achieved by using an Extend-
C18 (Agilent) column 2.1 × 15 mm, 1.8 μm. Elution 
solvents consist of 0.1% formic acid in acetonitrile 
and 0.1% formic acid in water in gradient mode at flow 
rate 250 μl•min-1. The injection volume was 1.0 μl. The 
high-resolution mass spectra (HRMS) were taken, 
respectively, on an Agilent 6230 TOF LC/MS (Agilent 
Technologies, Germany) with electrospray ionization. 
MS operating conditions were as following: positive 
ionization mode, gas temperature of 325 °C, nitro-
gen flow rate of 10 l/min, nebulizer pressure 40 psi, 
capillary voltage 3500 V and applied fragmentor was 
100 V. Internal reference mass 121.050873 m/z and 
922.009798 m/z (G1969-85001 ES-TOF Reference 
Mass Solution Kit, Agilent Technologies & Supelco) for 
all sample analyses were used. One full mass spectrum 
was acquired in profile mode, with mass range from 
m/z 50 to 1000.
Direct infusion of the cisplatin showed that there 
are no detectable ions found for cisplatin. Peak de-
tection and spectrum extraction were performed with 
MassHunter5.00 Software (Agilent).
Sample and standard preparation.  Fro-
zen cisplatin-plasma samples were thawed, 5% 
diethyldithiocarbamate (DDTC) 0.1N NaOH so-
lution was prepared. Cisplatin derivatives were 
prepared as follows — to 500 μl of plasma were 
added 100 μl of 5% DDTC solution. The sample 
was homogenized by vortexing approximately 
15–20 s and incubated for 15 min at 45 °C. After 
15 min 1400 μl of 70% acetonitrile were added to the 
sample. The sample was homogenized by vortexing 
about 15–20 s, and then placed into a centrifuge for 
15 min at 10,000 rpm. A 1.0 μl resulting upper layer 
aliquot was injected into the liquid chromatography-
mass spectrometry (LC-MS) system. The standard 
solutions of cisplatin derivative were prepared in the 
following concentrations: 0.5; 1.0; 5.0; 10.0; 25.0; 
50.0 and 100.0 μg/ml in acetonitrile. Solutions 
of each concentration were injected into LC-MS sys-
tem. All experiments were performed in triplicate. 
Calibration curves of standard solutions were con-
structed by plotting the average peak area against 
concentration, and a regression equation was com-
puted. A mixture of standard solutions was injected 
three times and the corresponding peak areas were 
recorded. The relative standard deviation was deter-
mined to be less than 1%. The obtained calibration 
curve showed linearity of correlation coefficient (R2) 
in the concentration range 0.99994.
Urine sample was collected for 6 h, 12 h, 24 h 
(Day 1), 48 h, 72 h (Day 3) and 96 h (Day 5) after re-
ceived cisplatin infusion. Collected urine for ice — 20 °C.
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Ethical aspects. Positive opinion of the trial 
preparation and development given the Latvian Uni-
versity of Research Institute of Cardiology clinical-
physiological study of medicinal and pharmaceutical 
products of clinical research ethics committee. Before 
the study, the patients were informed about the de-
tails of the study and approved the voluntary consent 
to participate in it. The study respondents of main-
tained confidentiality and anonymity.
Statistical analysis. Patient data were analysed 
using descriptive statistical methods, making a com-
parative analysis (t-test, chi-square (χ2) test by correla-
tion analysis (Pearson correlation coefficient)) using 
Microsoft Excel 2007 and SPSS software.
The aim of statistical analysis of research data 
was to evaluate the validity and theoretical probability 
distributions of the resulting measurements (distance, 
thickness, circumference and weight), as well as follow 
up on the statistical hypotheses. Therefore, the com-
mon (popular) descriptive statistical methods were 
very widely used in this study.
The variables, measured in relation scale and nor-
mally distributed (by Gaussian normal distribution) 
were analysed using parametric statistics methods. 
In other cases, non-parametric statistical methods 
were used. Hypotheses about the adequacy of the data 
to the normal probability distribution were mainly test-
ed by Kolmogorov — Smirnov test. The Student’s t-test 
was used to test uniformity of two arithmetic mean 
groups, for three or more groups of arithmetic mean 
the analysis of variance (ANOVA) was used. For com-
parison of the number of cases different statistical 
methods were used, such as χ2-test and Fisher’s exact 
test. The correlation and linear regression methods 
were used to predict the interaction between different 
variables and event analysis.
For statistical data processing first a database was 
created in software MS Excel, and then the data were 
converted for professional research data statistical 
processing program SPSS (Statistical Pacade for So-
cial Sciences) version 16.0 for Windows. All hypothesis 
tests used a duplex (2-tailed) statistical hypotheses 
and hypothesis was rejected if the probability (signifi-
cance level) was < 5% or p < 0.05.
The statistical software Statistica 6.0 was also used 
for processing of the data. In cases where data did not 
correspond to the normal distribution, a data transfor-
mation was performed, but after statistical analyses — 
opposite transformation. Non-parametric Spearman 
rank correlation was done in case of qualitative data. 
Differences between groups, correlations and regres-
sions were considered significant, if p < 0.05.
REsUlTs
HPLC-MS is an analytic chemical method, which 
combines physical separation of a blend by LC and 
mass analysis of a substance by MS. LC-MS analytical 
method is characterized by very high sensitivity and 
specificity. By using time of flight (TOF) detector, 
it is possible to determine compounds of highly com-
plex samples according to the mole mass, avoiding 
matrix effect interference.
Quantitative determination of pure cisplatin is quite 
complicated. Cisplatin as a chemical compound has 
not typical ultraviolet absorption therefore derivatisa-
tion should be performed by sodium DDTC in order 
to determine cisplatin by HPLC. This obtained com-
pound absorbs ultraviolet at 254 nm and is determined 
using LC.
Direct infusion of the cisplatin showed that there 
are no detectable ions found for cisplatin. The direct 
infusion into MS system of cisplatin DDTC derivative 
generate full scan spectra with a predominant ion 
at m/z 492 and m/z 640 correspond to [Pt(DDTC)2]+ 
and [Pt(DDTC)3]+ ions respectively (Fig. 1). This sug-
gests that after DDTC derivatization, cisplatin is con-
verted to Pt-(DDTC)2 and Pt-(DDTC)3.
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Fig. 1. High-resolution mass spectrum of cisplatin DDTC derivative 
from the standard solution, obtained by Agilent 6230 TOF LC/MS
Fig. 1 shows the magnified mass spectrum of a DDTC 
derivative of cisplatin from the standard solution, which 
is very close to spectrum from study by Yaroshenko 
et al. [5]. Other signals in mass spectra correspond to the 
signals formed by ions of different Pt isotopes.
In our further experiments cisplatin DDTC derivate 
which refers to formation of [Pt(DDTC)3]+ ion was used 
because of its higher intensity.
The base peak chromatogram in Fig. 2 shows the 
signal of peak from the most intense mass in mass 
spectrum of m/z 640, plotted versus time.
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Fig. 2. Base peak chromatogram at m/z 640 of cisplatin DDTC 
derivative Pt-(DDTC)3 in patient’s P01 urine after 12 h
Pharmacokinetic measurements of cispla-
tin in patients’ blood serum. The calibration curve 
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was designed from standard solutions of cisplatin 
derivative and cisplatin concentrations in μg/ml were 
determined from the standard curve for each sample 
of patient serum. Concentrations were converted into 
mg/l for calculations of pharmacokinetic data of cis-
platin. From the chromatograms of test samples during 
analyses it was concluded that the selected method 
can be used in quantitative determination of cisplatin 
in human blood serum. Separated peaks were sym-
metrical and did not overlap with other compounds 
existing in the matrix.
Changes of cisplatin concentration in blood serum 
at different time intervals were identified, where the 
key was to find the maximum concentration of cispla-
tin in certain period of time (Cmax). In this study Cmax 
of cisplatin was reached 2 h after cisplatin injection.
Small differences were observed in the elimination 
half-times (t½) for patients involved in this study. The 
t½ for one of the groups (P13; P14; P15 and P16) was 
observed higher almost by half than for other patients. 
This could be explained by patients being overweight 
as the average weight for this group was 97.21 kg. 
Data on the t½ for other patients were not significantly 
different, they were calculated as average values and 
applied to the calculations of following pharmacoki-
netic parameters for all patients (Table 1). 
From the equations that were calculated and ob-
tained using Excel 2013 software, individual elimination 
constants (kel) were calculated and shown as the de-
gree in equation (see Table 1). They are presented with 
a negative (−) sign, because it is a process of elimina-
tion, and kel indicates the percentage (%) of cisplatin 
eliminated per hour.
Table 1. Pharmacokinetic data of cisplatin. Calculated individual kel pre-
sented as the degree in equation with a negative (−) sign, because 
it is a process of elimination and kel indicates the percentage (%) of cispla-
tin eliminated per hour
Patients Equation C(0), mg/l
t½ 
of I phase, 
h
AUC, 
mg•h/l
CL, 
l/h t½ , h
P01 y = 1.17e−0.035x 1.17 16.90 33.43 3.74 19.80
P02 y = 1.40e−0.025x 1.40 22.35 56.00 2.23 27.72
P03 y = 0.73e−0.026x 0.73 11.95 28.08 4.45 26.65
P04 y = 0.85e−0.024x 0.85 18.24 35.42 3.53 28.88
P05 y = 0.91e−0.036x 0.91 12.60 25.28 5.93 19.25
P06 y = 0.74e−0.022x 0.74 16.12 33.64 4.46 31.50
P07 y = 1.58e−0.038x 1.58 18.24 41.58 3.61 20.38
P08 y = 0.76e−0.023x 0.76 15.40 33.04 4.54 30.13
P09 y = 1.72e−0.021x 1.72 15.07 81.90 1.59 33.00
P10 y = 2.22e−0.028x 2.22 16.90 79.29 1.64 24.75
P11 y = 1.92e−0.023x 1.92 27.72 83.48 1.56 30.13
P12 y = 2.24e−0.027x 2.24 23.90 82.96 1.57 25.67
P13 y = 0.45e−0.011x 0.45 8.06 40.91 3.18 63.00
P14 y = 0.69e−0.014x 0.69 9.76 49.29 2.64 49.50
P15 y = 0.62e−0.015x 0.62 9.36 41.33 3.15 46.20
P16 y = 0.74e−0.019x 0.74 9.76 38.95 3.34 36.47
P17 y = 0.98e−0.018x 0.98 38.50 54.44 2.39 38.50
P18 y = 1.07e−0.022x 1.07 31.50 48.64 2.67 43.31
P19 y = 0.97e−0.019x 0.97 36.47 51.05 2.55 46.20
P20 y = 1.17e−0.022x 1.17 31.50 53.18 2.44 38.50
Note: C — concentration; t½ — elimination half-time; AUC — area under the 
concentration curve; CL — clearance. 
The elimination rate constant kel was expressed 
from the established equation and then used to calcu-
late the total area under the concentration curve (AUC) 
and the clea rance (discharge of blood plasma volumes 
from the amount of substance per unit of time). Within 
the framework of our work, the AUC results ranged 
from 25.28 to 83.48 mg•h/l (see Table 1). The mean 
AUC result for all oncological patients, receiving cis-
platin at a dose of 125–150 mg, was 49.59 mg•h/l. 
Clearance estimates were summarized in Table 1. 
The results show that the clearance during treatment 
ranged 1.56–4.54 l/h. These results were very similar 
to the literature data, leading to the conclusion that 
results of our pharmacokinetic data are true and can 
be used for further research.
One of the pharmacokinetic parameters is the 
mean substance resistance time in the body (MRT — 
mean residence time). MRT = 1/kel, but since kel = 
0.693/t½, then the formula is = 1.44 x t½ (one divided 
by 0.693 equals 1.44). The mean t½ in elimination 
phase is 33.98 h, the average MRT was 48.93 h.
Determination of cisplatin in urine. Using the 
resulting calibration graph, amount of cisplatin in urine 
was calculated for all patients. Based on the concen-
tration in the urine, which was determined for 20 pa-
tients, concentration curves were obtained. To show 
how visually the curves look for patients depending 
on the dose, they were divided into groups of patients, 
depending on the received chemotherapy dose. Ac-
cordingly, three groups of patients were acquired.
Pharmacokinetic parameters such as renal clea-
rance, fraction of excreted substance in percentage 
and creatinine clearance were defined. It was observed 
that the AUC was higher for patients on the first day 
compared to the last day. Respectively, for those pa-
tients who received 130 mg or greater dose of cisplatin, 
the AUC lowered slowly in last two days of the study 
days. There are no data available to explain it. Perhaps 
this is related to the significant untapped biochemical 
processes, with cisplatin binding to mo lecules that 
hold cisplatin and do not let it to be removed gradually, 
as well as with cisplatin metabolism, which still has 
not been fully understandable. At the cisplatin dose 
of 130 mg and above, there was a change in the frac-
tion of excreted substance (%) by increase. Literature 
states that cisplatin excretes with urine very long time 
after the end of therapy, such as for patients receiving 
chemotherapy for a long time and who were followed 
for more than 10 years, in the urine were excreted 
1.26 ± 0.50 41 μg Pt after 24 h [6]. It would be useful 
to determine cisplatin urinary excretion for patients 
involved in the study after a long period of time, 
in parallel to determination of renal functions. This 
would allow the assessment of renal status, if it is not 
affected by the long cisplatin elimination after comple-
tion of therapy, or to determine the renal regeneration.
Changes of triglyceride levels in blood serum 
in patients receiving cisplatin therapy. Higher dose 
of cisplatin showed a significant association with in-
crease in triglyceride levels. Also higher body fat mass 
showed a relationship with increase in triglyceride 
levels. According to clinical tests, triglyceride levels 
in blood serum changed 24 h after received cisplatin 
therapy. The highest triglyceride levels were reached 
48–72 h after treatment.
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It was observed that triglycerides have a correlation 
with thickness of fatty tissue folds. The closest correla-
tion was with the thickness of fat tissue fold under the 
shoulder blade (p < 0.001; r = 0.56). We found a close 
correlation between BMI and triglyceride changes 
during chemotherapy (p = 0.001; r = 0.67). The results 
indicate that a higher BMI gives higher fluctuations 
of triglyceride levels in blood serum.
Levels of triglycerides in the blood serum in-
creased more at higher doses of cisplatin (Table 2). 
Higher triglyceride changes were observed at higher 
doses of cisplatin or greater dose differences. Increase 
of triglycerides in blood serum correlated with the 
person’s weight, especially the adipose tissue mass, 
greater changes were with increased weight. In gene-
ral, gender has not such a big role in the cisplatin dose 
application, but fat tissue mass is essential. Amount 
of adipose tissue mass contributes to an increase 
in serum triglycerides. In conclusion, the greater body 
fat mass can contribute to a greater rise of triglyceride 
level in blood serum (p < 0.001).
Separately were analysed the data of 20 oncologi-
cal patients, splitting them into two groups depending 
on the BMI ≥ 29 kg/m2 (see Table 2).
It was observed by Pearson correlation that the 
level of triglycerides in the blood affects the t½ of cis-
platin (p < 0.01). It is likely that cisplatin is eliminated 
more slowly from the blood serum at higher levels 
of triglycerides. Analyses of correlation between level 
of triglycerides and t½ show that by an increase in the 
level of triglycerides in the blood serum cisplatin t½ 
is prolonged (R2 Linear = 0.596) (Fig. 3).
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Fig. 3. Correlation between the levels of triglycerides and the 
t½ of cisplatin
Also cisplatin concentration in urine is higher 
and elimination takes longer time at elevated levels 
of triglycerides (see Table 2), where close correlation 
between fe (%) and concentration parameters was 
seen (p < 0.01). Also good correlation for BMI with 
fe (%) and concentration parameters was observed 
(p < 0.05), suggesting that overweight affects cis-
platin elimination from the body. It is concluded that 
cisplatin from the serum and urine is excreted more 
slowly in patients with obesity and also maintains 
a lasting increase of triglycerides in the blood. There 
are no research data in the literature at the moment 
for comparison.
Table 2. Analysis of triglycerides, pharmacokinetic and anthropometric data of patients receiving cisplatin therapy
BMI,  
kg/m2
Dose  
of cisplatin 
75 mg/m2
Trigly-
cerides 
in blood  
serum 1
Trigly-
cerides 
in blood  
serum 2
t½, h CL, l/h C, mg/l fe, %
BMI, kg/m2 Pearson  
correlation 1 −0.008 0.060 0.284 0.255 0.227 0.507* 0.502*
Sig. (2-tailed) 0.973 0.802 0.225 0.278 0.337 0.023 0.024
N 20 20 20 20 20 20 20 20
Dose of cisplatin 
75 mg/m2
Pearson  
correlation −0.008 1 0.105 0.016 −0.275 0.589** 0.381 0.389
Sig. (2-tailed) 0.973 0.659 0.947 0.240 0.006 0.098 0.090
N 20 20 20 20 20 20 20 20
Triglycerides 
in blood serum 1
Pearson  
correlation 0.060 0.105 1 0.798** 0.731** 0.073 0.077 0.446*
Sig. (2-tailed) 0.802 0.659 0.000 0.000 0.759 0.746 0.049
N 20 20 20 20 20 20 20 20
Triglycerides 
in blood serum 2
Pearson  
correlation 0.284 0.016 0.798** 1 0.772** 0.093 0.166 0.472*
Sig. (2-tailed) 0.225 0.947 0.000 0.000 0.698 0.483 0.036
N 20 20 20 20 20 20 20 20
t½, h Pearson 
correlation 0.255 −0.275 0.731** 0.772** 1 −0.239 −0.059 0.215
Sig. (2-tailed) 0.278 0.240 0.000 0.000 00.311 0.804 0.362
N 20 20 20 20 20 20 20 20
CL, l/h Pearson  
correlation 0.227 0.589** 0.073 0.093 −0.239 1 0.777** 0.685**
Sig. (2-tailed) 0.337 0.006 0.759 0.698 0.311 0.000 0.001
N 20 20 20 20 20 20 20 20
C, mg/l Pearson  
correlation 0.507* 0.381 0.077 0.166 −0.059 0.777** 1 0.823**
Sig. (2-tailed) 0.023 0.098 0.746 0.483 0.804 0.000 0.000
N 20 20 20 20 20 20 20 20
fe, % Pearson  
correlation 0.502* 0.389 0.446* 0.472* 0.215 0.685** 0.823** 1
Sig. (2-tailed) 0.024 0.090 0.049 0.036 0.362 0.001 0.000
N 20 20 20 20 20 20 20 20
Note: *Correlation is significant at the 0.05 level (2-tailed). **Correlation is significant at the 0.01 level (2-tailed). t1/2 — elimination half-time — time in which 
the concentration of pharmaceutical agent in the blood (plasma, serum) reduces by half; CL, l/h — the liberation amount of plasma volume from the sub-
stance per unit of time; C — concentration of cisplatin in urine, mg/l; fe, % — fraction of excreted substance in urine, which is usually expressed as percentage.
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DIscUssION
It is important to determine precisely a dose of che-
motherapy agent as inadequate high dose of medica-
tion can cause serious side effects and even death, but 
too low dose reduces the effectiveness of treatment 
and overall survival. Accurate determination of the dose 
is still debatable both through already mentioned cal-
culation formulas and by taking into account described 
toxicity of chemotherapy drugs, when the patient re-
ceives inadequate dose. Described studies on patients 
with obesity have trend not to prescribe the calculated 
dose, due to fear of side effects, but that is not always 
justified. It affirms the need for new and accurate meth-
ods of calculation for doses of chemotherapy drugs.
A LC-MS method was selected to prove that the 
body frame has a vital role in chemotherapy dosage, 
which would allow better prediction of the therapeutic 
toxicity. A new, innovative method was developed for 
derivatisation of cisplatin and following determination 
by MS with UHPLC-TOF [7], in cooperation with the 
Faculty of Chemistry at the University of Latvia.
Differences in the elimination of cisplatin were 
observed depending on the content of muscles or fat 
tissues in the body mass. It was observed that cisplatin 
is eliminated more slowly in patients with overweight 
(obesity) than in patients with normal body weight. Com-
paring results of the obtained total AUC with the scientific 
literature, we can conclude that they have a slight differ-
ence. In the scientific literature, which studied several 
groups of patients with different tumor types, including 
lung cancer, the AUC was calculated as the average of all 
the groups, which was 23.19 ± 2.052 mg•h/l [8, 9], but 
in our study the AUC results ranged 25.28–83.48 mg•h/l. 
The mean AUC for all in our study involved oncological 
patients was 49.59 mg•h/l. The difference in results 
can be explained by the different doses. The peak con-
centration increases with increasing dose of cisplatin 
and therefore the total AUC is bigger. In research study, 
described in the literature, doses of cisplatin received 
ranged from 50 mg to 100 mg [8], but in this work have 
been stu died and analysed the patients who received 
cisplatin at a doses of 125–150 mg. Comparison of the 
cisplatin dose to AUC in both studies, a large difference 
between the results was not observed. In the literature 
reviewed study clearance calculations were carried out 
that during treatment ranged from 2.30 l/h up to 7.98 l/h, 
but in our calculations they were between 1.56 l/h and 
4.54 l/h. These results were very similar to those in the 
described study, which suggests that pharmacokinetic 
data of our study are true and can be used for further 
research.
HPLC-MS is used for detection of a variety of sub-
stances and medicines in biological solutions. It was 
used in our study to determine the concentration of cis-
platin from the constituent Cisplatin in the blood serum 
and urine of oncological patients. MS spectra with 
a signal at m/z 640, which corresponds to [Pt(DDTC)3]+ 
ions, were obtained during analysis of samples. Ac-
quired bands were symmetrical and did not overlap 
with other existing matrix compounds.
A new, innovative method was developed for derivati-
sation of cisplatin and following determination by MS with 
UHPLC-TOF. Pharmacokinetic parameters of cisplatin 
were determined for twenty patients with lung cancer 
diagnosed in stage III. Cisplatin was measured by stan-
dard curve concentrations in mg/ml. Approximately 
at the average dose of 135 mg, the mean Cmax in twenty 
patients was 2487.03 mg/ml, which was very close 
to the literature data. Cmax for all patients ranged from 
795.7 mg/ml up to 6429.1 mg/ml, this could be ex-
plained by a variety of doses administered individually 
to each patient. Elderly patients often have impaired 
renal function, which does not allow 100% cisplatin dose 
application in order to avoid serious adverse reactions. 
The t½ was observed almost 50% higher for patient 
group (P13, P14, P15, and P16). That could be explained 
by the increase in body weight for this group (an average 
of 97.21 kg), so that proves the hypothesis that cisplatin 
is eliminated more slowly in patients with a higher body 
weight (obesity) than in patients with normal body weight. 
This confirmed one of our working hypotheses. Clear-
ance during treatment ranged from 1.56 l/h to 4.54 l/h. 
These results were very similar to the literature data and 
suggest that resulting pharmacokinetic data in our study 
are true and can be used for further research.
Despite the fact that there are many studies on phar-
macokinetics of cisplatin, many of these stu dies did not 
specify the pharmacokinetic data or often mentioned 
that the data are consistent with the norm. It was con-
cluded from the review of literature data on the pharma-
cokinetics of cisplatin that there are no certain limits and 
averages, and the mechanism of action of cisplatin is not 
clear. There are no whole some data on the pharmaco-
kinetics of cisplatin, which can be influenced by various 
factors such as the patient’s overweight, age, gender, 
co-morbidities, drug storage and administration, etc.
It was concluded from results of our study that there 
are two significant factors that affected the level of tri-
glycerides in the blood. One of them is the higher dose 
of cisplatin, the other is the larger body fat mass. Since 
patients received multiple courses of chemotherapy, 
then a gradual increase in trigly cerides was observed 
with each subsequent dose of cisplatin, especially in pa-
tients with obesity. Positive correlation (Pearson) was 
found for triglyceride level changes, depending on the 
cisplatin dose, between the initial triglyceride levels 
and body fat, muscle and bone masses (p < 0.001). In-
creased dose of cisplatin showed a significant associa-
tion with increased levels of triglycerides. Also, a higher 
body fat mass showed association with an increased 
level of triglycerides. Correlation was found between 
level of triglycerides and fat fold thickness. The clo sest 
correlation was with fat fold thickness under the shoul-
der blade (p < 0.001; r = 0.56). A close correlation was 
found between BMI and triglyceride changes during 
chemotherapy (p = 0.001; r = 0.67). Results indicate 
that higher BMI gives greater fluctuations of triglyc-
eride levels in blood serum. The adipose tissue mass 
became more important for cisplatin dose determina-
tion in women (p < 0.05), although women were not the 
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biggest of statistical groups. Both the adipose tissue 
mass (p < 0.001) and muscle mass (p < 0.05) were 
essential in dose determination, especially at the dose 
differences (p < 0.01). Overall, the gender has not such 
a big role in the cisplatin dose application, essential 
is the fat tissue mass. Adipose tissue mass contributes 
to an increase in serum triglycerides.
Cisplatin is characterized by cumulation (accumu-
lation) of dose, when part of the medication remains 
from the previous administration, particularly at doses 
higher than 100 mg/m2 [10]. It should further be stud-
ied the relationship between cisplatin dose cumulation 
and an increase in triglyceride levels in the blood, and 
obesity. Associated between increased triglyceride 
levels and cisplatin treatment is unclear. It is important 
to mention that cancer patients have abnormal metabolic 
processes in the body. Cancer patients with weight loss 
have increased triglyceride and fatty acid metabolism 
in comparison with patients without weight loss [11]. 
An increased triglyceride concentration in blood plasma 
was observed in weight losing cancer patients compared 
to stable weight cancer patients, indicating on enhanced 
lipolysis [12]. This makes it difficult to precisely analyse 
changes in triglyceride levels in the blood serum.
Results of our study showed a significant rela-
tionship between the dose of cisplatin and the level 
of triglycerides in the blood serum. Also the study, 
carried out with stem cell tumors, mentioned that the 
level of triglycerides in the blood serum tended to in-
crease in the group of cisplatin therapy patients, but 
this trend was not statistically significant [13]. However, 
in another study by a 5-year follow-up after cisplatin 
therapy of testicle tumor, there were no significant dif-
ferences in plasma triglyceride levels among patients 
with cisplatin therapy and without it [14]. In the longer 
term cisplatin may have no effect on triglycerides in the 
blood plasma, as it has been observed in animal stu-
dies that a few days after cisplatin therapy there were 
elevated triglyceride levels in blood plasma and also 
in proximal renal tubules, thus causing cisplatin toxicity 
in the kidneys [15, 16]. This is an important factor for 
patients, especially in women with a high-carbohydrate 
diet, because additional accumulation of triglycerides 
as a result of overproduction of insulin may increase 
cisplatin nephrotoxicity [17, 18]. Additional research 
study is necessary to carry out on relationship of cis-
platin pharmacokinetics with obesity and levels of tri-
glycerides in the blood. Higher dose of cisplatin and 
increased body fat mass are important risk factors 
for elevated triglyceride levels in the blood serum. 
Determination of the level of triglycerides in blood 
plasma may serve as an additional indicator and toxic-
ity marker for higher toxicity of cisplatin.
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